Navigation Links
Alkylating in Medical News
...ylaxis, tumor lysis syndrome, skin reactions, and other malignancies.
TREANDA has a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct way...
...1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...
...1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
... developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents. ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trial...
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
...hocyte Infusion II-35 Hematological Cancer Drug Classes II-35 Hypomethylating Agents & Antimetabolites II-35 Bisphosphonates II-36 alkylating Agents and DNA-Damaging Agents II-36 DNA-Repair Enzyme Inhibitors II-36 Histone Deacetylase Inhibitor II-36 Immunomodulators II-36 Pro...Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
...age of 50. TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in com......1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...
...1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...
The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates
...ation makes brain cancer cells more responsive to anticancer drugs known as alkylating agents. While brain cancer patients with the MGMT alteration respond better to the commonly-used alkylating agent temozolomide, the new TCGA research found that treatment also appears...Vion Reports 2008 Second Quarter and Six-Month Results
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen......rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
... developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents. ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trial...
Vion Pharmaceuticals to Appeal Nasdaq Delisting
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...Alkylating in Medical Technology
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
...d on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent ......body-drug conjugate was well-tolerated in cynomolgous monkeys and mouse models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) The effectiveness of a cleavable linker over a non-cleavable linker when used with MGB...
...B-CLL. Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare Phar...
...-CLL. Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare Ph...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
...mage and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine. Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the tr...
Alkylating in Biological News
Researchers reveal structure of protein that repairs damage to cancer cells
...me strategy to all kinds of other protein-DNA complexes. The AlkB and ABH2 proteins repair alkylation damage to DNA, including the damage caused by alkylating cancer treatments. Alkylation is the addition of certain chemical groups to DNA and is particularly harmful to rapidly growing cells such as cancerous...Alkylating in Biological Technology
...iate treatment, never progress beyond the early stages of the disease.
About Clearazide
Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoria...
...platform. Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA minor-groove binding alkylating agent) which is attached to an antibody using a stable peptide-based linker. Medarex believes that its ADC technology overcomes many of the key develo...
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinica...
Telik Reports Preclinical Results at AACR Annual Meeting
...hanism of TLK58747; Abstract # 4515 Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for enzymat...lease an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein). Key findings: TLK58747 inhibited th...Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
...8:00 to 12:00 p.m. local time on Sunday, April 19, 2009. "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19,...Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
...pulation particularly attractive." About Onrigin Onrigin (laromustine) Injection, formerly known as Cloretazine(R) (VNP40101M), is a novel alkylating agent. Onrigin has been evaluated in over 800 patients in 16 clinical trials to date, including a pivotal Phase II trial in patients sixty years of ag......platform. Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA minor-groove binding alkylating agent) which is attached to an antibody using a stable peptide-based linker. Medarex believes that its ADC technology overcomes many of the key develo...
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
...vative cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelog...Vion Reports 2008 First Quarter Results
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...Vion Pharmaceuticals Files Plan With Nasdaq
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...Vion Reports 2007 Fourth Quarter and Year-End Results
...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen......rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinica...
Alkylating in Biological Dictionary
...ation, a free radical, a carbanion or a carbene . alkylating agents are widely used in chemistry... An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an...
Other TagsOther Contents
(Date:5/23/2013)... May 23, 2013 Netsmart today ... 100 listing of healthcare information technology (HIT) providers for 2013. ... 2013 issue of Healthcare Informatics magazine. Netsmart’s ranking ... , “Our strong continued growth is largely due to our ... tumultuous period of healthcare where resources are scarce, the demand ...
(Date:5/23/2013)... Hormones drive many aspects of our lives: ... sleep quality, sex drive, how productive we are, soft skin ... driven by declining hormone levels as we age. , The ... abundant foundation or base from which the body makes hormones. ... about age 25, when we are “in our prime”; and ...
(Date:5/23/2013)... 23, 2013 Each month Dwell magazine ... stylish eco-friendly hybrids and electric cars. Nowhere in America are ... the symbolic green car capital. Thankfully this June, Green Car ... and drive back to Dwell on Design 2013 ... During the first two days of Dwell on Design, June ...
(Date:5/23/2013)... CNIC researchers have discovered that the daily clearance of ... stem cells from the bone marrow into the bloodstream, ... Cell ., Neutrophils are leukocytes (white blood cells) ... other disease organisms. To perform their function, these cells ... microorganisms. However, release of these substances in the wrong ...
(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...
Breaking Medicine News(10 mins):Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Health2Go Announces Research That DHEA Helps Depression 2Health News:Health2Go Announces Research That DHEA Helps Depression 3Health News:Health2Go Announces Research That DHEA Helps Depression 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:Discarded immune cells induce the relocation of stem cells 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2[0] Netsmart Named to Healthcare Informatics Top 100 List[0] Health2Go Announces Research That DHEA Helps Depression[0] Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013[0] Discarded immune cells induce the relocation of stem cells[0] Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month
(Date:5/22/2013)... potential environmental and human health effects from disposal ... has led scientists to recommend stronger government policies ... (Li-ion) battery materials. That,s the conclusion of a ... Science & Technology . , Oladele A. Ogunseitan ... become mainstays for powering everything from smart phones ...
(Date:5/22/2013)... on how climate change will affect interactions between species ... Journal of Animal Ecology . This knowledge, they say, ... of how species are likely to be impacted by ... recognition among biologists that climate change is affecting how ... going to have very important consequences for the stability ...
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
Breaking Biology News(10 mins):UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |